Department of Neurology, Kliniken Südostbayern-Klinikum Traunstein, Traunstein, Germany; Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.
Department of Neurology, Kliniken Südostbayern-Klinikum Traunstein, Traunstein, Germany.
J Stroke Cerebrovasc Dis. 2014 Feb;23(2):361-6. doi: 10.1016/j.jstrokecerebrovasdis.2013.05.004. Epub 2013 Jun 12.
Thrombolysis is the most successful therapy in acute ischemic stroke. Limitations comprise strict eligibility criteria including many contraindications for thrombolysis, and in particular clinical situations lack of evidence-based data resulting in recommendations based on single experiences. Therefore, the risk-benefit effect of thrombolysis in the presence of brain tumor is unknown.
We conducted a systematic literature research of electronic databases (MEDLINE, Goggle Scholar) covering the period from 1990 to 2012 including search terms "thrombolysis," "stroke," "brain tumor," and "intracranial neoplasm." In addition, we report 1 new case of a 71-year-old patient with a large right frontal meningioma who fully recovered with thrombolysis from a severe ischemic stroke.
Our literature research retrieved 12 patients with different brain tumors who were treated with thrombolysis for different reasons. Intracerebral hemorrhage occurred in 1 patient (8.3%) with a glioblastoma, and in the other 11 patients (91.7%), no hemorrhage was documented. In the subgroup of 8 stroke patients, both patients with a glioblastoma had no stroke but rather a focal seizure. Two of 3 patients with meningiomas showed a very good benefit from thrombolysis.
In summary, very limited data exist about thrombolysis in patients with brain tumors. Differentiation of tumor by additional neuroimaging before thrombolysis in ischemic stroke is recommended as thrombolysis might be considered in extra-axial benign appearing neoplasms (eg, meningioma) but is not advisable in intra-axial primary or metastatic neoplasm. Further reporting of thrombolysis in patients with brain tumors is recommended.
溶栓治疗是急性缺血性脑卒中最成功的治疗方法。限制包括严格的入选标准,包括许多溶栓治疗的禁忌症,特别是缺乏循证医学数据的临床情况,导致基于单一经验的建议。因此,存在脑肿瘤时溶栓的风险效益尚不清楚。
我们对电子数据库(MEDLINE、Goggle Scholar)进行了系统的文献检索,涵盖了 1990 年至 2012 年的时间段,包括搜索词“溶栓”、“中风”、“脑肿瘤”和“颅内肿瘤”。此外,我们报告了 1 例新的 71 岁患者,该患者患有大型右额脑膜瘤,因严重缺血性中风接受溶栓治疗后完全康复。
我们的文献检索共检索到 12 例不同脑肿瘤患者因不同原因接受溶栓治疗。1 例(8.3%)脑胶质母细胞瘤患者发生脑出血,其他 11 例(91.7%)患者未发生出血。在 8 例中风患者亚组中,2 例脑胶质母细胞瘤患者无中风,而是局灶性癫痫发作。3 例脑膜瘤患者中有 2 例溶栓获益非常好。
总的来说,关于脑肿瘤患者溶栓治疗的数据非常有限。建议在缺血性中风前通过额外的神经影像学对肿瘤进行鉴别,因为溶栓治疗可能适用于轴外良性肿瘤(如脑膜瘤),但不适用于轴内原发性或转移性肿瘤。建议进一步报告脑肿瘤患者的溶栓治疗情况。